FMP
Adverum Biotechnologies, Inc.
ADVM
NASDAQ
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
10.19 USD
-0.81 (-7.95%)
About
ceo
Dr. Laurent Fischer
sector
Healthcare
industry
Biotechnology
website
https://www.adverum.com
exchange
NASDAQ
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorpor...
CIK
0001501756
ISIN
US00773U1088
CUSIP
00773U108
Address
800 Saginaw Drive
Phone
650 656 9323
Country
US
Employee
121
IPO Date
Jul 31, 2014
Summary
CIK
0001501756
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
00773U108
ISIN
US00773U1088
Country
US
Price
10.19
Beta
0.79
Volume Avg.
283.58k
Market Cap
211.49M
Shares
-
52-Week
7.1-29.7
DCF
-0.31
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.88
P/B
-
Website
https://www.adverum.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest ADVM News
It looks like there's no news available.
